Barrett's esophagus medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 62: Line 62:


===Medications to relieve symptoms and control gastroesophageal reflux include:===
===Medications to relieve symptoms and control gastroesophageal reflux include:===
*H2-receptor antagonists:
**These are competitive blockers of [[histamine]] at [[H2]] [[receptor]] blockers, it inhibits acid secretion from gastric parietal cells. Drugs in this categories are:
**Ranitidine
**Famotidine
**Nizatidine
**Cimetidine
*[[Proton pump inhibitor]]:
**These acts by inhibiting of the H+/K+ -adenosine triphosphatase (ATPase) enzyme system which further inhibits gastric acid secretions by gastric parietal cells. Various types of [[proton pump inhibitors]] are:
**Omeprazole
**Lansoprazole
**Esomeprazole
**Dexlansoprazole
**Rabeprazole
**Pantoprazole
* [[Antacids]] after meals and at [[bedtime]]
* [[Antacids]] after meals and at [[bedtime]]
* [[Cholinergic]] agents
* [[Cholinergic]] agents
* [[Histamine]] [[H2]] [[receptor]] blockers
*Photosensitizers:
* Promotility agents
**Porfimer, a photosensitizer which is used along with photodynamic therapy.
* [[Proton pump inhibitors]]: [[Proton pump inhibitor]] [[drugs]] have not yet been proven to prevent [[esophageal]] [[cancer]].
**It acts by absorbing light and transforms into short-lived singlet state, further transformed to a reactive triplet state.
**During the triplet state, it produces free radical which react with cell membranes and causes damage to the mitochondria, endoplasmic reticulum, and/or plasma membranes.


==References==
==References==

Revision as of 02:38, 6 February 2018

Barrett's Esophagus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Barrett's Esophagus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Endoscopic Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Barrett's esophagus medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Barrett's esophagus medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Barrett's esophagus medical therapy

CDC on Barrett's esophagus medical therapy

Barrett's esophagus medical therapy in the news

Blogs on Barrett's esophagus medical therapy

Directions to Hospitals TreatingBarrett's esophagus

Risk calculators and risk factors for Barrett's esophagus medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2] Amresh Kumar MD [3]

Overview

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Medical Therapy

According to the American College of Gastroenterology, indication for the medical therapy in Barrett's esophagus patients are:[1][2]

  • Patients with BE should receive once-daily PPI therapy. Routine use of twice-daily dosing is not recommended unless necessitated because of poor control of reflux symptoms or esophagitis.
  • Aspirin or nonsteroidal anti-inflammatory drugs should not be routinely prescribed to patients with BE as an antineoplastic strategy. Similarly, other putative chemopreventive agents currently lack sufficient evidence and should not be administered routinely.

Treatment may be important even if you do not feel any symptoms.

Lifestyle changes include:

Medications to relieve symptoms and control gastroesophageal reflux include:

  • H2-receptor antagonists:
    • These are competitive blockers of histamine at H2 receptor blockers, it inhibits acid secretion from gastric parietal cells. Drugs in this categories are:
    • Ranitidine
    • Famotidine
    • Nizatidine
    • Cimetidine
  • Proton pump inhibitor:
    • These acts by inhibiting of the H+/K+ -adenosine triphosphatase (ATPase) enzyme system which further inhibits gastric acid secretions by gastric parietal cells. Various types of proton pump inhibitors are:
    • Omeprazole
    • Lansoprazole
    • Esomeprazole
    • Dexlansoprazole
    • Rabeprazole
    • Pantoprazole
  • Antacids after meals and at bedtime
  • Cholinergic agents
  • Photosensitizers:
    • Porfimer, a photosensitizer which is used along with photodynamic therapy.
    • It acts by absorbing light and transforms into short-lived singlet state, further transformed to a reactive triplet state.
    • During the triplet state, it produces free radical which react with cell membranes and causes damage to the mitochondria, endoplasmic reticulum, and/or plasma membranes.

References

  1. "Diagnosis and Management of Barrett's Esophagus | American College of Gastroenterology".
  2. Amano Y, Kinoshita Y (2008). "Barrett esophagus: perspectives on its diagnosis and management in asian populations". Gastroenterol Hepatol (N Y). 4 (1): 45–53. PMC 3394474. PMID 22798736.

Template:WH Template:WS